299 related articles for article (PubMed ID: 20948444)
1. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
2. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
Hu P; Arias RS; Sadun RE; Nien YC; Zhang N; Sabzevari H; Lutsiak ME; Khawli LA; Epstein AL
Clin Cancer Res; 2008 Jan; 14(2):579-88. PubMed ID: 18223234
[TBL] [Abstract][Full Text] [Related]
3. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
4. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Wen Y; Wang CT; Ma TT; Li ZY; Zhou LN; Mu B; Leng F; Shi HS; Li YO; Wei YQ
Cancer Sci; 2010 Nov; 101(11):2325-32. PubMed ID: 20804499
[TBL] [Abstract][Full Text] [Related]
6. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity.
Haque A; Stanley AC; Amante FH; Rivera Fde L; Zhou Y; Kuns RD; Yardley V; Sakaguchi S; Hill GR; Engwerda CR
J Immunol; 2010 Mar; 184(5):2583-92. PubMed ID: 20139272
[TBL] [Abstract][Full Text] [Related]
8. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
11. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.
Imai N; Ikeda H; Tawara I; Wang L; Wang L; Nishikawa H; Kato T; Shiku H
Cancer Sci; 2009 Jul; 100(7):1317-25. PubMed ID: 19432889
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis.
Patel M; Xu D; Kewin P; Choo-Kang B; McSharry C; Thomson NC; Liew FY
Eur J Immunol; 2005 Dec; 35(12):3581-90. PubMed ID: 16285015
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.
Boczkowski D; Lee J; Pruitt S; Nair S
Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460
[TBL] [Abstract][Full Text] [Related]
17. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
18. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity.
Kamimura Y; Iwai H; Piao J; Hashiguchi M; Azuma M
J Immunol; 2009 Mar; 182(5):2708-16. PubMed ID: 19234165
[TBL] [Abstract][Full Text] [Related]
19. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]